title: Alpha-1 blockers. A new generation of antihypertensive agents.
abstract: Alpha-1 blockers have certain disadvantages over conventional and antihypertensive therapies in their haemodynamic profile and metabolic effects. This paper reviews the development of alpha-blockade, the therapeutic efficacy of prazosin, the prototype alpha-1 blocker, and the rationale for the once-daily antihypertensive compounds, terazosin and doxazosin. These drugs offer a useful alternative to first- or second-line therapy in suitable hypertensive patients, particularly with their potentially beneficial effects on serum lipids.
authors.affiliation: Abbott Laboratories, Maidenhead, Berkshire, U.K.
authors.forename: J E
authors.initials: JE
authors.lastname: Humphreys
authors.forename: M A
authors.initials: MA
authors.lastname: Waite
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011224:Prazosin / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D011224:Prazosin